Absci (ABSI) Stock Price, Quote, News & History | Benzinga

SPY767.08−0.33%QQQ719.51−1.29%BTC/USD80,825.13−0.91%DIA516.84+0.23%GLD381.04+1.34%TLT79.99+1.39%

Absci Corp (ABSI) Stock Price, Quote, News & History

ABSINASDAQ

Trade with Public

Trade with Public

$8.74

-0.36-3.96%

Last update: Oct 15, 7:02 AM

$8.60

-0.50-5.49%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

-

Close

$8.74

Volume / Avg.

12.81K / 3.43M

Day Range

$8.60 - $8.60

52 Wk Range

2.24 - 12.06

Market Cap

$1.56B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

26.55%

Days to Cover

7.52

Recent Absci Corp News

Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.

Avi Kapoor

Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.

Avi Kapoor

Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report

Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.

Vandana Singh

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.

Avi Kapoor

Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI

Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A decline, signaling a shift in AI adoption.

Surbhi Jain

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-108.08M

Investing Cash Flow (TTM)

-12.73M

Financing Cash Flow (TTM)

174.44M

Free Cash Flow (TTM)

-108.97M

Capital Expenditure (TTM)

-890.00K

Net Change in Cash (TTM)

53.63M

Analyst Trends and Forecast

1

Jul

2

Aug

3

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.30B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

848.47

PB Ratio (TTM)

6.10

Earnings Yield % (TTM)

-9.03%

Earnings Yield % (FWD)

-2.06%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.43

Company Debt

Total Debt

$150.00K

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$2.00M

Total Cash

$107.87M

Debt to Equity

0.02

Issuance of Debt (TTM)

-$2.00M

Repayment of Debt (TTM)

-$2.00M